TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds

NACompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2016

Conditions
Nasolabial Folds, Wrinkles
Interventions
DEVICE

TEOSYAL® RHA Global Action

"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."

DEVICE

TEOSYAL® RHA Deep Lines

"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."

Trial Locations (5)

Unknown

United States, Alabama, Birmingham

United States, California, Beverly Hills

United States, Santa Monica, Santa Monica

United States, Florida, Coral Gables

United States, Massachusetts, Chestnut Hill

All Listed Sponsors
collaborator

ethica Clinical Research Inc.

INDUSTRY

lead

Teoxane SA

INDUSTRY

NCT02195427 - TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds | Biotech Hunter | Biotech Hunter